Literature DB >> 10540156

Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus.

P Gargiulo1, J Goldberg, B Romani, R Schiaffini, P Ciampalini, W P Faulk, J A McIntyre.   

Abstract

Diabetes mellitus is associated with vascular and neurological complications. We have investigated the presence of antibodies to phospholipids and to phospholipid binding plasma proteins in blood samples collected from 68 clinically and biochemically characterized type I and type II diabetic patients and from 252 healthy blood donor controls. Each sample was analysed for antibodies to three phospholipids (cardiolipin, phosphatidylserine and phosphatidylethanolamine), the antibody isotypes (IgA, IgG and IgM), and whether antibody activity was plasma protein-dependent. Patients were considered to have anti-phospholipid antibodies when one or more of these 18 tests was found above predetermined control values. The results of these experiments revealed an increased incidence of anti-phospholipid antibodies in diabetic patients compared with control subjects. The incidence of IgA isotype to phosphatidylethanolamine was higher than the incidence of other isotypes to other phospholipids, and their reactivities were independent of phospholipid-associated proteins. In addition, these antibody findings were studied for associations with prothrombin degradation products, activated factor VII and activated protein C, and with the incidence of diabetic complications. The anti-phosphatidylethanolamine antibody association with proliferative retinopathy was significant.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10540156      PMCID: PMC1905396          DOI: 10.1046/j.1365-2249.1999.01014.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  51 in total

Review 1.  Pathogenesis of diabetic microangiopathy: an overview.

Authors:  A H Barnett
Journal:  Am J Med       Date:  1991-06-24       Impact factor: 4.965

2.  Anticardiolipin antibody titers in patients with myocardial infarction.

Authors:  D Foley-Nolan; R Woods; L Choudhry; P Byrne; D Sugrue; R J Coughlan; C Barry
Journal:  Am J Cardiol       Date:  1991-09-15       Impact factor: 2.778

3.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Koike
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

4.  The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies.

Authors:  R A Fields; H Toubbeh; R P Searles; A D Bankhurst
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

Review 5.  Pathobiology of endothelial and other vascular cells in diabetes mellitus. Call for data.

Authors:  M Lorenzi; E Cagliero
Journal:  Diabetes       Date:  1991-06       Impact factor: 9.461

6.  Increased plasma levels of IgA-IgG immune complexes and anti-F(ab')2 antibodies in patients with type 2 (non insulin-dependent) diabetes mellitus and microangiopathy.

Authors:  D Casiglia; E Giardina; G Scarantino; G Triolo
Journal:  Diabetes Res       Date:  1990-12

7.  Polymeric IgA and IgA rheumatoid factor decrease the capacity of serum to solubilize circulating immune complexes in patients with primary IgA nephropathy.

Authors:  P F Schena; A Pastore; R A Sinico; V Montinaro; A Fornasieri
Journal:  J Immunol       Date:  1988-07-01       Impact factor: 5.422

8.  Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy.

Authors: 
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-07       Impact factor: 4.799

9.  Abnormal serum immunoglobulin concentrations in patients with diabetes mellitus.

Authors:  S Rodríguez-Segade; M F Camiña; J M Paz; R Del Río
Journal:  Clin Chim Acta       Date:  1991-12-16       Impact factor: 3.786

10.  Laboratory and clinical features in systemic lupus erythematosus patients with or without anticardiolipin antibodies.

Authors:  J J Vogel; G Reber; P de Moerloose
Journal:  Thromb Res       Date:  1991-06-01       Impact factor: 3.944

View more
  8 in total

1.  Immune complex formation in human diabetic retina enhances toxicity of oxidized LDL towards retinal capillary pericytes.

Authors:  Dongxu Fu; Jeremy Y Yu; Mingyuan Wu; Mei Du; Ying Chen; Souzan A Abdelsamie; Yanchun Li; Junping Chen; Michael E Boulton; Jian-Xing Ma; Maria F Lopes-Virella; Gabriel Virella; Timothy J Lyons
Journal:  J Lipid Res       Date:  2014-03-10       Impact factor: 5.922

Review 2.  The role of antiphospholipid antibodies (aPls) in infertile women: the long-lasting experience.

Authors:  Zdenka Ulcova-Gallova
Journal:  Reprod Med Biol       Date:  2014-10-07

3.  Anticardiolipin antibodies in proliferative diabetic retinopathy: An additional risk factor.

Authors:  Maha Shahin; Amany M El-Diasty; Mohamed Mabed
Journal:  Saudi J Ophthalmol       Date:  2009-08-05

4.  Anticardiolipin antibodies in patients with type 2 diabetes mellitus.

Authors:  José María Calvo-Romero; Esther María Lima-Rodríguez
Journal:  Clin Med Res       Date:  2009-02-26

5.  Mechanistic dissection of diabetic retinopathy using the protein-metabolite interactome.

Authors:  Ambrose Teru Patrick; Weilue He; Joshua Madu; Srinivas R Sripathi; Seulggie Choi; Kook Lee; Faith Pwaniyibo Samson; Folami L Powell; Manuela Bartoli; Donghyun Jee; Diana R Gutsaeva; Wan Jin Jahng
Journal:  J Diabetes Metab Disord       Date:  2020-06-18

6.  Therapeutic Apheresis in Metabolic Syndrome.

Authors:  V A Voinov
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2018-05

7.  Antiphospholipid antibodies in patients with dysglycaemia: A neglected cardiovascular risk factor?

Authors:  Giulia Ferrannini; Elisabet Svenungsson; Barbro Kjellström; Kerstin Elvin; Giorgia Grosso; Per Näsman; Lars Rydén; Anna Norhammar
Journal:  Diab Vasc Dis Res       Date:  2020 Mar-Apr       Impact factor: 3.291

Review 8.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.